title: Angiocentric immunoproliferative lesions of the lymph node.
abstract: Clinicopathologic features in 14 cases of lymph node-involved angiocentric immunoproliferative lesions (AILs) are reported. They were selected from 900 cases of lymphoproliferative disorders registered at the Department of Pathology, Fukuoka University. Four cases showed a histologic feature of AIL grade II (AIL-II) and 10 had angiocentric lymphoma (AIL-III). Immunohistologically, transformed B cells were mixed with a large number of small T cells in AIL-II. In AIL-III, there were five cases with B-cell lymphoma, and three had peripheral T-cell lymphoma with no expression of natural-killer (NK)-associated antigens. In the remaining two cases, lymphoma cells expressed both T-cell- and NK-associated antigens. These findings indicate that lymph node-involved AILs are rarely occurring (1.6%) and phenotypically different from sinonasal and cutaneous AILs. Furthermore, NK-associated antigen-positive AILs were found to rarely involve the lymph node. For Epstein-Barr virus (EBV) infection, seven cases of AILs showed many atypical lymphocytes that were positive for EBV-encoded RNA (EBER-1) by using the in situ hybridization analysis. Among them, six cases had latent membrane protein (LMP) positive and EBV nuclear antigen 2 (EBNA-2) negative atypical lymphocytes. The pattern of latent EBV infection was similar to that of Hodgkin's disease, but differed from those of sinonasal T-cell lymphoma and other subtypes of non-Hodgkin's lymphoma. Clinically, 12 patients, including all 4 AIL-II, died within 22 months of the onset of the disease, despite intensive therapy, suggesting that lymph node-involved AILs have a poor prognosis.
authors.affiliation: Department of Pathology, School of Medicine, Fukuoka University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takeshita
authors.forename: M
authors.initials: M
authors.lastname: Akamatsu
authors.forename: K
authors.initials: K
authors.lastname: Ohshima
authors.forename: J
authors.initials: J
authors.lastname: Suzumiya
authors.forename: M
authors.initials: M
authors.lastname: Kikuchi
authors.forename: N
authors.initials: N
authors.lastname: Kimura
authors.forename: N
authors.initials: N
authors.lastname: Uike
authors.forename: T
authors.initials: T
authors.lastname: Okamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000956:Antigens, Viral / Q000032:analysis; D001483:Base Sequence; D004268:DNA-Binding Proteins / Q000032:analysis; D003937:Diagnosis, Differential; D019309:Epstein-Barr Virus Nuclear Antigens; D005260:Female; D004854:Herpesvirus 4, Human / Q000737:chemistry; D006801:Humans; D016130:Immunophenotyping; D017403:In Situ Hybridization; D008198:Lymph Nodes / Q000737:chemistry / Q000473:pathology*; D008230:Lymphomatoid Granulomatosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D016601:RNA-Binding Proteins / Q000032:analysis; D012269:Ribosomal Proteins; D014763:Viral Matrix Proteins / Q000032:analysis
chemical_list: D000956:Antigens, Viral; D004268:DNA-Binding Proteins; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D016601:RNA-Binding Proteins; D012269:Ribosomal Proteins; D014763:Viral Matrix Proteins; C067169:RPL22 protein, human